Project Grant R01CA295774
Award Date
1/9/25
Completion Date
12/31/29
Dollars Obligated
$547K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $154,642 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Targeting the Evolving Immunopeptidome of Metastatic Colorectal Cancer," aims to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic lesion patient-derived organoids (PDOs) through mass spectrometry. This will identify conserved...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory provides $640,583 to enhance the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor activity within the tumor microenvironment. The research aims to delineate the mechanisms by which PPARD activation improves CD8+ T cell...
The National Cancer Institute (NCI) awarded a Project Grant, under CFDA 93.394 Cancer Detection and Diagnosis Research, to Case Western Reserve University (CWRU) for $654,681 starting on December 1, 2024. The goal of this 5-year project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The research aims to design and evaluate these nanovaccines, assess their therapeutic...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $333,504 to The Washington University to conduct research on the role of peritoneal myeloid cells in colorectal cancer peritoneal metastasis and implications for immunotherapy. The award commences on July 1, 2025 and is scheduled for completion by July 31, 2027. The key objectives of this research project are to: Profile immune cell phenotypical changes in the peritoneal fluid and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $176,712 to the University of Pittsburgh to conduct research on the role of CD91-mediated signaling in cancer immunosurveillance. The research aims to develop a new mouse model to test the importance of CD91 signaling in response to tumor-derived heat shock proteins (HSPs) for priming T cell responses against nascent, emerging tumors. The goal is to better understand the mechanisms by...
This Project Grant award, totaling $482,236 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop a new targeted therapy for patients with HER2-low metastatic colorectal cancer (mCRC). The principal investigator at the Sloan-Kettering Institute for Cancer Research will conduct a Phase 2 clinical trial to evaluate the safety and efficacy of combining the antibody-drug conjugate trastuzumab deruxtecan (T-DXD) with the...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $137,322 to Trustees of Boston University to develop disulfated polyamidosaccharide (DISULPAS) nanoparticles for the targeted delivery of chemotherapeutics to metastasizing cancer cells. The goal is to create a synthetic fucoidan mimetic that can more consistently bind to the P-selectin protein, which is upregulated on many tumor cells and plays a key role in metastasis. The project will...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the University of California, San Diego (UCSD) to develop slow-release CPMV (Cowpea Mosaic Virus)-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to formulate CPMV-laden slow-release devices, establish and tune the release rates, confirm the structural integrity and biological activity of the released CPMV, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) in the amount of $121,857 aims to systematically investigate how anti-cancer drugs modulate T cells in the tumor microenvironment. The key objectives are to: Conduct in silico screening to identify anti-cancer drugs impacting T cell effector function, activation, stemness, and proliferation (Aim I). Perform single-cell CRISPR knockout screening to determine anti-cancer drug targets...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...